These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23194488)

  • 21. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA).
    Inglis SC; McMurray JJ; Böhm M; Schaufelberger M; van Veldhuisen DJ; Lindberg M; Dunselman P; Hjalmarson A; Kjekshus J; Waagstein F; Wedel H; Wikstrand J;
    Eur J Heart Fail; 2010 Jul; 12(7):698-705. PubMed ID: 20501489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.
    Maggioni AP; Fabbri G; Lucci D; Marchioli R; Franzosi MG; Latini R; Nicolosi GL; Porcu M; Cosmi F; Stefanelli S; Tognoni G; Tavazzi L;
    Eur Heart J; 2009 Oct; 30(19):2327-36. PubMed ID: 19717850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tailored therapy for heart failure: the role of biomarkers.
    Wollert KC
    Eur Heart J; 2012 Sep; 33(18):2246-8. PubMed ID: 22611133
    [No Abstract]   [Full Text] [Related]  

  • 24. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.
    Ueland T; Aukrust P; Nymo SH; Kjekshus J; McMurray JJ; Wikstrand J; Block D; Zaugg C; Gullestad L
    J Card Fail; 2015 Feb; 21(2):153-9. PubMed ID: 25451704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Askevold ET; Gullestad L; Nymo S; Kjekshus J; Yndestad A; Latini R; Cleland JG; McMurray JJ; Aukrust P; Ueland T
    PLoS One; 2015; 10(8):e0133970. PubMed ID: 26288364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [No reason to start treatment with statins in patients with moderate to severe heart failure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.
    Abdul-Rahim AH; Perez AC; Fulton RL; Jhund PS; Latini R; Tognoni G; Wikstrand J; Kjekshus J; Lip GY; Maggioni AP; Tavazzi L; Lees KR; McMurray JJ; ;
    Circulation; 2015 Apr; 131(17):1486-94; discussion 1494. PubMed ID: 25810334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Ridker PM
    Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.
    Broch K; Ueland T; Nymo SH; Kjekshus J; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Cleland JG; Aukrust P; Gullestad L
    Eur J Heart Fail; 2012 Mar; 14(3):268-77. PubMed ID: 22302661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
    Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
    Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Rogers JK; Jhund PS; Perez AC; Böhm M; Cleland JG; Gullestad L; Kjekshus J; van Veldhuisen DJ; Wikstrand J; Wedel H; McMurray JJ; Pocock SJ
    JACC Heart Fail; 2014 Jun; 2(3):289-97. PubMed ID: 24952697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Serebruany VL
    Cardiology; 2011; 120(2):84-8. PubMed ID: 22142620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial.
    Marchioli R; Levantesi G; Silletta MG; Barlera S; Bernardinangeli M; Carbonieri E; Cosmi F; Franzosi MG; Latini R; Lucci D; Maggioni AP; Moretti L; Nicolosi GL; Porcu M; Rossi MG; Tognoni G; Tavazzi L;
    Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):735-48. PubMed ID: 19589110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-terminal probrain natriuretic peptide as a predictor of short-term outcomes in acute myocardial infarction.
    Puri A; Narain VS; Mehrotra S; Dwivedi SK; Saran RK; Puri VK
    Indian Heart J; 2005; 57(4):304-10. PubMed ID: 16350675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
    Motsko SP; Russmann S; Ming EE; Singh VP; Vendiola RM; Jones JK
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1214-22. PubMed ID: 19780020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.